Profile Image

Staff Profile

Edit

Career Summary

Biography

Dr Verrills research interests centre on understanding the signalling pathways involved in cancer development, progression and resistance to chemotherapy induced cell death. Her research involves cell biology and biochemistry, translation into clinically relevant mouse models of disease, and analysis of primary patient samples. During her PhD studies Dr Verrills used powerful proteomics techniques, including being one of the first in Australia to use difference in-gel electrophoresis (DIGE) technology, to discover novel protein alterations that confer chemotherapy resistance in childhood leukaemia. In postdoctoral studies Dr Verrills further applied her proteomics skills to the investigation of respiratory disease, and has identified clinical biomarkers for asthma and chronic obstructive pulmonary disease. These proteins are now targets for patent applications and ongoing investigations into the development of diagnostics and improved therapies. Her postdoctoral studies in respiratory disease led to an interest in signalling pathways, with particular interest in the multifunctional protein phosphatase, PP2A. This led her to establish a research group investigating the role of protein phosphatase 2A (PP2A) in cellular functions. Her group has discovered novel roles for PP2A in cellular function and disease, including myeloid leukaemias, melanoma and asthma, and demonstrated that PP2A activation is a potential strategy for improved therapies (e.g. senior author papers in Cancer Research and Cell Signalling, and co-authored papers in Nature Medicine, Journal of Clinical Investigation; J Biol Chem; BBA; Cell Death & Diff). She has developed a unique panel of PP2A molecular reagents (shRNA, overexpression constructs, antibodies, pharmacological activators/inhibitors), and established strategic collaborations which has enabled her to expand her investigations of PP2A into the study of breast cancer.

Her PhD was awarded from Macquarie University in 2005, for which she received a Vice-Chancellor’s Commendation for Excellence in Research. In 2006 Dr Verrills received a highly competitive NHMRC Peter Doherty Postdoctoral Fellowship. Through this fellowship she also received a scholarship to the Australian Academy of Science “Science at the Shine Dome” meeting. In 2006 she also became the inaugural recipient of the Hunter Medical Research Institute (HMRI) Competitive Research Fund for Early Career Researchers in Cancer. In 2010 Dr Verrills was appointed to an ongoing academic position (Lecturer) at the University of Newcastle, however in 2011 she was awarded a Cancer Institute NSW Early Career Research Development Award, and after deferring this for a year for maternity leave, she took up this fellowship in Dec 2011.

Research outputs: Dr Verrills has 28 research publications, with 13 as first or senior author, appearing in journals of good to high impact in the field (average IF 6.4) and are well cited (>800 to date; average 59 cites/yr; h-index 14). The importance of her work has also been featured in editorial articles (Fojo, T (2006) J Natl Cancer Inst 98: 1363 and Ojima and Ferlini (2003) Chem Biol 10: 583).

Funding: Since 2006 Dr Verrills has attracted >$3M in competitive research grant/fellowship funding, from the NHMRC, Cancer Council NSW, Anthony Rothe Foundation, Ramaciotti Foundation, Cancer Institute NSW, Cure Cancer Australia Foundation, and the Hunter Medical Research Institute (HMRI). She has also attracted infrastructure funding from the ARC, ACRF, Ramaciotti Foundation and the Cancer Institute NSW of > $6.4M.

Awards: Dr Verrills research is internationally competitive and recognised through continued publications, presentations at international and national meetings, and international and national awards. These include the 2012 Newcastle Innovations ‘Rising Star Award’; 2010 HUPO Young Guns Award; 2007 Voiceless Eureka Prize; the 2007 Young Tall Poppy Award; the 2007 University of Newcastle Vice Chancellor’s Award for Research Excellence; 2004 Biochemical Journal Young Investigator Award, presented to the best young researcher at the 12th International Conference on Second Messengers and Phosphoproteins, Montreal, Canada; the Merck Sharp Dohm “Best of the Best” Award and the Cure Cancer Australia Foundation Award, both presented at the 2004 Australian Health and Medical Research (ASMR) Congress. In 2003 Dr Verrills was awarded the University of Sydney Medal for Excellence in Medical Research, presented to the best young researcher at the ASMR NSW Conference, and was a finalist in the Cure Cancer Australia Foundation’s Young Researcher of the Year Award.

Service to the discipline: Her expertise in the field of proteomics and cancer biology results in invitations to peer review grant applications (e.g. NHMRC, ARC, Wellcome Trust; AICR; Cure Cancer Australia Foundation), ~20 manuscripts/year for a variety of journals (e.g. Blood, Oncogene, Cancer Research; Molecular Cancer Therapeutics; Proteomics), and ~2 PhD theses/year. In 2012 and 2013 Dr Verrills was a panel member for the NHMRC Cancer Biology & Oncology grant review panel. She has also served on the Leukaemia Foundation PhD and Postdoctoral fellowship review panels. Dr Verrills is a mentor in a University run mentoring program for early career researchers, and has given many lectures to undergraduate, graduate, and school students on careers in medical research.

Invited presentations: In 2012 Dr Verrills was an invited speaker at the International meetings: Phophatases in Disease, Vic; 37th Annual Lorne Proteins Meeting, Vic; Garvan Signalling Meeting, Sydney; Australian Society for Medical Research (ASMR) NSW Branch Scientific Meeting, Sydney. She was also session chair for the ASMR NSW Branch Scientific Meeting and the New Directions in Leukaemia Research, Sunshine Coast. She regularly presents her research to other universities and research institutes. For example, in 2012 she presented at the Lowy Cancer Centre, UNSW, in 2010 at IMVS, Adelaide, and at Pharmaxis in Sydney. In past years she has presented at Macquarie University, The Oncology Research Unit, Westmead, and the Children’s Cancer Institute Australia, Sydney.

Student Supervision: Dr Verrills has been primary supervisor for 3 PhD students to completion, and a further student recently submitted. These students received a number of awards during their studies. She has supervised four Honours students (all received 1st Class).

Conference coordination: Dr Verrills was co-convenor for the international meeting: HMRI Translational Cancer Conference – Pathways to Tailored Therapies, Newcastle, 2008, and was on the organising committee for the 2006 HMRI Conference on Translational Cancer Research and again for the 2013 Conference.

Committees: Dr Verrills is an active member of the Hunter Medical Research Institute Cancer Research Program Steering committee, where she has taken a major role in building up the activities of the program including preparing strategic plans, infrastructure and program funding applications, inviting speakers and establishing an annual research seminar day to foster internal research collaborations. She is also a member of the University of Newcastle’s Australian Biomolecular Research Facility steering committee.

Community engagement: She has a strong commitment to the advancement and promotion of medical research in our society. As part of her community involvement she has disseminated her research through the print, radio, and television media, and has presented her research to the local community as a guest speaker at Rotary and Lions Clubs, and HMRI, Cure Cancer Australia, and Cancer Council NSW charity events. Through the Tall Poppy Campaign she has also presented her research to High School students across NSW, and has established relationships with her local school communities to foster and encourage an interest in studying science.

Current position: In Dec 2011 Dr Verrills returned from maternity leave as a Research Only Academic at the University of Newcastle, working 0.6FTE, funded by a Cancer Institute NSW ECR Development Award.

Qualifications

  • Bachelor of Science (Honours), Macquarie University, 12/05/1999

Research

Research keywords

  • Breast Cancer
  • Cancer
  • Chemotherapy resistance
  • Leukaemia
  • Protein phosphatase 2A
  • Proteomics
  • Signal transduction

Research expertise

Dr Verrills research interests centre on understanding the molecular changes involved in cancer progression and chemotherapy resistance. By using powerful proteomics techniques, including being one of the first in Australia to use difference in-gel electrophoresis (DIGE) technology, she has discovered novel protein alterations that confer chemotherapy resistance in childhood leukaemia. These proteins are now targets for ongoing investigations to develop improved therapies for relapsed leukaemia patients. Dr Verrills is currently investigating the role of the signaling protein, protein phosphatase 2A, in cancer. Using shRNA and overexpression transfection of normal and cancer cell lines, coupled with molecular and biochemical analyses such as PCR, immunoblotting, immunoprecipitation, immunofluorescence, 2D-DIGE and mass spectrometry, she is determining the role of mutant PP2A and specific PP2A subunits in the development of leukaemia and breast cancer.

Fields of Research

CodeDescriptionPercentage
060100Biochemistry And Cell Biology75
111500Pharmacology And Pharmaceutical Sciences15
111200Oncology And Carcinogenesis10

Memberships

Body relevant to professional practice.

  • Member - American Association of Cancer Research
  • Member - Australian Society for Medical Research

Committee/Associations (relevant to research).

  • Committee member - HMRI Cancer Research Group Steering Committee
  • Organising committee member - HMRI Conference on Translational Cancer Research

NHMRC Committee

  • Member - NHMRC Grant Review Panel

Appointments

Peter Doherty Biomedical Fellow
National Health & Medical Research Council (Australia)
01/01/2006 - 01/07/2010

Awards

Honours.

1998Bill Cantwell prize for Excellence in Biology
Macquarie University (Australia)
This award is given to exceptional students who top the honours year.

Other

2003Australian Postgraduate Award 2001-2003
Macquarie University (Australia)

PhD Scholarship

2003Australian Proteome Analysis Facility Scholarship 2001-2003
Australian Proteome Analysis Facility (Australia)
This award gave a top-up to the APA for my PhD candidature.

Recognition.

20052005 - Doctor of Philosophy, Vice Chancellor Commendation.
Macquarie University (Australia)
My PhD thesis was passed without need for corrections and I received a letter of commendation from the Vice Chancellor for excellence in research.
20032003 - Cure Cancer Australia Foundations Young Researcher of the Year Award Finalist.
Cure Cancer Australia Foundation (Australia)
Cure Cancer Australia Foundation is a major supporter of cancer research, raising funds to provide competitive research funding schemes and research awards. The Young Researcher Awards are a major event within the Australian medical and scientific communities as the process draws the very best young cancer researchers from right around Australia.

Research Award.

20042004 - Cure Cancer Australia Foundation Award
Cure Cancer Australia Foundation (Australia)
This prize was awarded for the best postdoctoral or student presentation in cancer research at the National Scientific Meeting of the Australian Society for Medical Research.
20042004 - Merck Sharp Dohm Best of the Best Award Australian Health and Medical Research Congress
Australian Society of Medical Research (Australia)
This is a highly competitive and prestigious research award. There were 28 societies represented at this meeting and each society put forward their best candidate, drawn from postdoctoral scientists and students. I shared the overall top prize with one other candidate.
2004Biochemical Journal Young Investigator Award - 12th International Conference on Second Messengers an
The Biochemical Journal (Canada)
The Biochemical Journal is Europes leading scientific journal in the field and gives the award to the most deserving young scientist based upon presentation of their work to a judging panel of international experts. This award is highly competitive and prestigious, with 157 international postdoctoral and student candidates in 2004.
20032003 - University of Sydney Medal for Excellence in Medical Research
Australian Society of Medical Research (Australia)
This prestigious award was presented for the best postdoctoral or student research presentation at the NSW state branch ASMR meeting.

Invitations

Amersham Biosciences Technical Seminar Series. Brisbane; Adelaide; Melbourne; Sydney.
GE Biosciences, Australia (Conference Presentation - non published.)
2003
Protemics for cancer research
Oncology Research Unit, Childrens Hospital, Westmead., Australia (Invitation to give research seminar)
2003
Proteome analyses reveals novel mechanisms of resistance to anticancer agents.
Oncology Research Unit, Childrens Hospital, Westmead., Australia (Invitation to give research seminar)
2003
New technologies meets functional proteomics.
ComBio 2002, Australia (Invited conference presentation)
2002

Administrative

Administrative expertise

Dr Verrills undetakes many administrative tasks, including managing the budgets for her grants. Some duties include obtaining product quotes, ordering, safety and ethics applications, co-ordinating multi investigator grant applications, and organising research seminar series and workshops.

Teaching

Teaching keywords

  • Cancer
  • Drug resistance
  • Proteomics

Teaching expertise

Dr Verrills is a strong supporter of fostering research students. She has supervised two Honours student (both received 1st Class), and is currently supervising one Honours and three PhD students. Dr Verrills is a fulltime research academic, however she does guest lecture for 2nd and 3rd year BBiomed Sci courses in Proteomics, Bioinformatics, Cancer, and Drug Resistance.

Edit

Highlighted Publications

For publications that are currently unpublished or in-press, details are shown in italics.

YearCitationAltmetricsLink
2006Verrills NM, Po'Uha ST, Liu MLM, Liaw TYE, Larsen MR, Ivery MT, et al., 'Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia', Journal of the National Cancer Institute, 98 1363-1374 (2006) [C1]
2006Verrills NM, Liem NL, Liaw TYE, Hood BD, Lock RB, Kavallaris M, 'Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia - an in vivo study', Proteomics, 6 1681-1694 (2006) [C1]
2013Collison AM, Hatchwell LM, Verrills NM, Wark PA, Pereira De Siqueira AL, Tooze MK, et al., 'The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity', Nature Medicine, 19 232-237 (2013) [C1]

Publications

For publications that are currently unpublished or in-press, details are shown in italics.

Click on a category title below to expand the list of citations for that specific category.

Chapter (1 outputs)

YearCitationAltmetricsLink
2011Smith AM, Roberts KG, Verrills NM, 'Ser/Thr phosphatases: The new frontier for myeloid leukemia therapy?', Myeloid Leukemia - Basic Mechanisms of Leukemogenesis, Intech, Croatia 123-148 (2011) [B1]

Journal article (32 outputs)

YearCitationAltmetricsLink
2014Goldie BJ, Dun MD, Lin M, Smith ND, Verrills NM, Dayas CV, Cairns MJ, 'Activity-associated miRNA are packaged in Map1b-enriched exosomes released from depolarized neurons.', Nucleic Acids Research, 42 9195-9208 (2014) [C1]
2014Hatchwell L, Girkin J, Morten M, Collison A, Mattes J, Foster PS, et al., 'Salmeterol attenuates chemotactic responses in rhinovirus-induced exacerbation of allergic airways disease¿by modulating protein phosphatase 2A', Journal of Allergy and Clinical Immunology, (2014)
2014Gilan O, Diesch J, Pearson RB, Hannan RD, Dhillon AS, Amalia M, et al., 'PR55a-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity', Oncogene, 0 (2014)
2014Hoffman A, Carpenter H, Kahl R, Watt LF, Dickson PW, Rostas JAP, et al., 'Dephosphorylation of CaMKII at T253 controls the metaphase-anaphase transition', Cellular Signalling, 26 748-756 (2014)
2013Collison AM, Hatchwell LM, Verrills NM, Wark PA, Pereira De Siqueira AL, Tooze MK, et al., 'The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity', Nature Medicine, 19 232-237 (2013) [C1]
2012Tay KH, Jin L, Tseng HY, Jiang CC, Ye Y, Thorne RF, et al., 'Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress', Cell Death and Disease, 3 e337 (2012) [C1]

Co-authors: Rick Thorne, Xu Zhang

2012Bradbury P, Mahmassani M, Zhong J, Turner K, Paul A, Verrills NM, O'Neill GM, 'PP2A phosphatase suppresses function of the mesenchymal invasion regulator NEDD9', Biochimica Et Biophysica Acta-Molecular Cell Research, 1823 290-297 (2012) [C1]
2012Skelding KA, Dickson PW, Verrills NM, Rostas JA, 'Progression through mitosis can be controlled by dephosphorylation of CaMKII at T253', JOURNAL OF NEUROCHEMISTRY, 123 31-31 (2012) [E3]
2011Verrills NM, Irwin JA, He XY, Wood LG, Powell H, Simpson JL, et al., 'Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease', American Journal of Respiratory and Critical Care Medicine, 183 1633-1643 (2011) [C1]
2011Skelding KA, Rostas JA, Verrills NM, 'Controlling the cell cycle: The role of calcium/calmodulin-stimulated protein kinases I and II', Cell Cycle, 10 631-639 (2011) [C1]
2011Chang H-Y, Jennings PC, Stewart JL, Verrills NM, Jones KT, 'Essential role of protein phosphatase 2A in metaphase II arrest and activation of mouse eggs shown by okadaic acid, dominant negative protein phosphatase 2A, and FTY720', Journal of Biological Chemistry, 286 14705-14712 (2011) [C1]
2011Roberts KG, McDougall FK, Verrills NM, 'Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers - Response', Cancer Research, 71 2404-2404 (2011) [C3]
2010Kranias G, Watt L, Carpenter HC, Holst J, Ludowyke R, Strack S, et al., 'Protein phosphatase 2A carboxymethylation and regulatory B subunits differentially regulate mast cell degranulation', Cellular Signalling, 22 1882-1890 (2010) [C1]
2010Roberts KG, Smith AM, McDougall FK, Carpenter HC, Horan MP, Neviani P, et al., 'Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers', Cancer Research, 70 5438-5447 (2010) [C1]
2010Skelding KA, Suzuki T, Gordon SL, Xue J, Verrills NM, Dickson PW, Rostas JA, 'Regulation of CaMKII by phospho-Thr253 or phospho-Thr286 sensitive targeting alters cellular function', Cellular Signalling, 22 759-769 (2010) [C1]
2008Ong V, Liem NLM, Schmid MA, Verrills NM, Papa RA, Marshall GM, et al., 'A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts', JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 324 434-442 (2008) [C1]
2007Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, et al., 'FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia', Journal of Clinical Investigation, 117 2408-2421 (2007) [C1]
2006Verrills NM, Po'Uha ST, Liu MLM, Liaw TYE, Larsen MR, Ivery MT, et al., 'Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia', Journal of the National Cancer Institute, 98 1363-1374 (2006) [C1]
2006Sim AT, Ludowyke RI, Verrills NM, 'Mast cell function: Regulation of degranulation by serine/threonine phosphatases', Pharmacology & Therapeutics, 112 425-439 (2006) [C1]
2006Verrills NM, Liem NL, Liaw TYE, Hood BD, Lock RB, Kavallaris M, 'Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia - an in vivo study', Proteomics, 6 1681-1694 (2006) [C1]
2006Verrills NM, 'Clinical proteomics: present and future prospects', Clinical Biochemist Reviews, 27 99-116 (2006) [C2]
2005Kavallaris M, Verrills NM, 'Improving the targeting of tubulin-binding agents: lessons from drug resistance studies', Current Pharmaceutical Design, 11 1719-1733 (2005) [C1]
2005Schevzov G, Vrhovski B, Bryce NS, Elmir S, Qiu MR, O''Neil GM, et al., 'Tissue-specific tropomyosin isoform composition', Journal of Histochemistry and Cytochemistry: imaging the spectrum of cell biology, 53 557-570 (2005) [C1]
2004Don S, Verrills NM, Liaw TY, Liu ML, Norris MD, Haber M, Kavallaris M, 'Neuronal-associated microtubule proteins class III ß-tubulin ad MAP2c in neuroblastoma: Role in resistance to microtubule-targeted drugs', Molecular Cancer Therapeutics, 3 1137-1146 (2004) [C1]
2003Mackintosh JA, Choi HY, Bae SH, Veal DA, Bell PJ, Ferrari BC, et al., 'A fluorescent natural product for ultra sensitive detection of proteins in one-dimensional and two-dimensional gel electrophoresis', Proteomics, 3 2273-2288 (2003) [C1]
2003Verrills NM, Kavallaris M, 'Drug resistance mechanisms in cancer cells: A proteomics perspective', Current Opinion in Molecular Therapeutics, 5 258-265 (2003) [C1]
2003Verrills NM, Flemming CL, Liu M, Ivery MT, Cobon GS, Norris MD, et al., 'Microtubule alterations and mutations induced by desoxyepothilone B: Implications for drug-target interactions', Chemistry and Biology, 10 597-607 (2003) [C1]
2003Verrills NM, Walsh BJ, Cobon GS, Hains PG, Kavallaris M, 'Proteome analysis of Vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations', Journal of Biological Chemistry, 278 4508-4509 (2003) [C1]
2001Kavallaris M, Verrills NM, Hill BT, 'Anticancer therapy with novel tubulin-interacting drugs', DRUG RESISTANCE UPDATES 4 (6): 392-401 DEC 2001, 392-401 (2001) [C1]
2000Verrills NM, Harry JH, Walsh BJ, Hains PG, Robinson ES, 'Cross-matching marsupial proteins with eutherian mammal databases: Proteome analysis of cells from UV-induced skin tumours of an opossum (Monodelphis domestica)', ELECTROPHORESIS 21 (17): 3810-3822 NOV 2000, 3810-3822 (2000) [C1]
2000Cordwell SJ, Nouwens AS, Verrills NM, Basseal DJ, Walsh BJ, 'Subproteomics based upon protein cellular location and relative solubilities in conjunction with composite two-dimensional electrophoresis gels', ELECTROPHORESIS 21 (6): 1094-1103 APR 2000, 1094-1103 (2000) [C1]
1999Cordwell SJ, Nouwens AS, Verrills NM, McPherson JC, Hains PG, Van Dyk DD, Walsh BJ, 'The microbial proteome database - an automated laboratory catalogue for monitoring protein expression in bacteria', ELECTROPHORESIS 20 (18): 3580-3588 DEC 1999, 3580-3588 (1999) [C1]
Show 29 more

Conference (21 outputs)

YearCitationAltmetricsLink
2013Dun MD, Smith AM, Kahl RGS, Smith ND, Khanna A, Don AS, et al., 'Unraveling the mechanism of action: drugs that activate the tumor suppressor 2A.', CANCER RESEARCH, Washington, DC (2013) [E3]
2012Skelding KA, Dickson PW, Verrills NM, Rostas JA, 'Dephosphorylation of CAMKII at T253 controls progression through metaphase', Abstracts. Australian Neuroscience Society 32nd Annual Meeting, Gold Coast, Queensland (2012) [E3]
2011Collison AM, Hatchwell LM, Pereira De Siqueira AL, Don A, Verrills NM, Foster PS, Mattes J, 'The development of house dust mite-induced allergic airways disease is regulated by a novel E3 ubiquitin ligase-dependent deactivation of a protein phosphatase', Respirology, Perth, WA (2011) [E3]
2011Hatchwell LM, Collison AM, Pereira De Siqueira AL, Foster PS, Verrills NM, Don A, et al., 'A novel E3 ubiquitin ligase links rhinovirus infection to exacerbation of asthma', Respirology, Perth, WA (2011) [E3]
2010Irwin J, Verrills NM, He XY, Powell H, Wood LG, Gibson PG, 'Proteomic biomarkers as novel clinical diagnostics for airway disease', Abstract Book. Human Proteome World Congress Sydney 2010, Sydney, NSW (2010) [E3]

Co-authors: Lisa Wood, Peter Gibson

2010Gilan O, Jastrezebski K, Diesch J, Verrills NM, Hannan RD, Dhillon AS, 'Functional regulation of the Fra-1/AP-1 Transcription factor via interactions with protein phosphatase 2A', OzBio 2010: The Molecules of Life - from Discovery to Biotechnology. Poster Abstracts, Melbourne, Australia (2010) [E3]
2010Skelding KA, Xue J, Suzuki T, Verrills NM, Dickson PW, Rostas JA, 'Mechanisms of phosphorylation-sensitive CaMKII targeting', Proceding of the Australian Neuroscience Society, Sydney, NSW (2010) [E3]
2010Skelding KA, Verrills NM, Dickson PW, Rostas JA, 'Regulation of proliferation of neuroblastoma cells by CaMKII', Proceding of the Australian Neuroscience Society, Sydney, NSW (2010) [E3]
2010Verrills NM, Roberts KG, Smith AM, McDougall FK, Carpenter HC, Neviani P, et al., 'Targeting the tumour suppressor, PP2A, as a novel therapy for acute myeloid leukaemia', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
2009Skelding KA, Liao X, Verrills NM, Fluechter L, Dickson PW, Rostas JA, 'CaMKII phosphorylation at T253 alters neuronal growth rates and morphology', Journal of Neurochemistry, Busan, Korea (2009) [E3]
2009Rostas JA, Skelding KA, Verrills NM, Suzuki PW, Dickson T, 'CaMKII binding partners vary with cell type and phosphorylation state', Journal of Neurochemistry, Busan, Korea (2009) [E3]
2009Skelding KA, Liao X, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Functional consequences of CaMKII phosphorylation at THR253 in neurons', ANS 2009 Abstracts: Posters, Canberra, ACT (2009) [E3]
2009Rostas JA, Skelding KA, Liao X, Verrills NM, Dickson PW, 'Regulation of CaMKII by targeting', Proceedings of the 2nd Australia-China Biomedical Research Conference, - (2009) [E3]
2009Kranias G, Cottrell LF, Carpenter HC, Sim AT, Verrills NM, 'Protein phosphatase 2A carboxymethylation and regulatory B subunits differentially regulate mast cell degranulation', FEBS Journal, Prague, Czech Republic (2009) [E3]

Co-authors: Alistair Sim

2008Skelding KA, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Identification of CaMKII binding proteins in brain sensitive to CaMKII phosphorylation state', Proceedings of the Australian Neuroscience Society, Hobart, TAS (2008) [E3]
2008Skelding KA, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Development of a novel method for the identification of CaMKII binding proteins', Journal of Neurochemistry, Shanghai, China (2008) [E3]
2007Roberts KG, Ashman LK, Sim AT, Verrills NM, 'Regulation of protein phosphatase 2A (PP2A) B subunits by Bcr/Abl: Potential targets for chronic myeloid leukemia', AACR Meeting Abstracts Online (Abstracts of the 98th AACR Annual Meeting), Los Angeles (2007) [E3]
2007Roberts KG, Ashman LK, Sim ATR, Verrills NM, 'Altered expression of PP2A regulatory subunits in chronic myelogenous leukemia: Identifying targets for improved therapies', BLOOD, Atlanta, GA (2007)
2006Verrills NM, Carpenter HC, Sim AT, 'Disruption of Actin-containing Protein Phosphatase 2A Complexes Regulates Cell Motility in Neuroblastoma Cells', Molecular & Cellular Proteomics, California, USA (2006) [E3]

Co-authors: Alistair Sim

2006Chang MHY, Engelander J, Verrills NM, Tait AS, Kavallaris M, 'Differential proteomic analysis of low-level anti-microtubule resistance in acute lymphoblastic leukaemia (Poster presentation)', 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (European Journal of Cancer Supplements, Vol 4, no. 12), Prague, Czech Republic (2006) [E3]
2004Schevzov G, Vrhovski B, Bryce NS, Elmir S, Qiu M, Yang N, et al., 'Tropomyosin antibodies identify functionally distinct populations of actin filaments', MOLECULAR BIOLOGY OF THE CELL, Washington, DC (2004)
Show 18 more
Edit

Grants and Funding

Summary

Number of grants54
Total funding$8,375,362

- Indicates that the researcher may be seeking students for this project.

Click on a grant title below to expand the full details for that specific grant.

2014 (7 grants)

Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia$600,000
Funding Body: Cancer Institute NSW

Project Team
Doctor Matt Dun, Doctor Nikki Verrills, Associate Professor Martin Larsen
SchemeRole
Early Career FellowshipInvestigator
Total AmountFunding StartFunding Finish
$600,00020142016
GNo:G1300952

Targeting a tumour in breast cancer$37,800
Funding Body: Pink Frangipani Ball Organising Committee

Project Team
Doctor Nikki Verrills
SchemeRole
Research ProjectChief Investigator
Total AmountFunding StartFunding Finish
$37,80020142014
GNo:G1400881

Defining the role of shwachman-bodien diamond syndrome protein (SBDS) in PP2A inhibition in acute myeloid leukaemia (AML).$25,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Matt Dun, Doctor Nikki Verrills
SchemeRole
Project GrantInvestigator
Total AmountFunding StartFunding Finish
$25,00020142014
GNo:G1301442

Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia$25,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Matt Dun, Doctor Nikki Verrills
SchemeRole
Project GrantInvestigator
Total AmountFunding StartFunding Finish
$25,00020142014
GNo:G1301353

Myr-C310: A new treatment for childhood leukaemia$25,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Kathryn Skelding, Doctor Nikki Verrills
SchemeRole
Project GrantInvestigator
Total AmountFunding StartFunding Finish
$25,00020142014
GNo:G1301349

Preclinical testing of a novel therapeutic strategy for breast cancer $25,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Nikki Verrills, Doctor Kathryn Skelding
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$25,00020142014
GNo:G1301439

Identification of BAALC as a new target for the treatment of acute myeloid leukaemia $20,000
Funding Body: University of Newcastle

Project Team
Doctor Kathryn Skelding, Doctor Nikki Verrills
SchemeRole
Near Miss GrantInvestigator
Total AmountFunding StartFunding Finish
$20,00020142014
GNo:G1301404

2013 (4 grants)

Targeting PP2A to improve the therapeutic efficacy of mutant BRAF inhibitors in melanoma$359,250
Funding Body: Cancer Council NSW

Project Team
Professor Xu Dong Zhang, Doctor Nikki Verrills, Doctor Chen Chen Jiang
SchemeRole
Research GrantInvestigator
Total AmountFunding StartFunding Finish
$359,25020132015
GNo:G1200388

Targeting BAALC as a new treatment for acute myeloid leukaemia$25,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Kathryn Skelding, Doctor Nikki Verrills
SchemeRole
Project GrantInvestigator
Total AmountFunding StartFunding Finish
$25,00020132013
GNo:G1301348

Ultra-Low Temperature Cryogenic Freezer$24,596
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Doctor Jude Weidenhofer, Doctor Rick Thorne, Doctor Kathryn Skelding, Doctor Nikki Verrills, Doctor Pradeep Tanwar, Associate Professor Phillip Dickson, Conjoint Associate Professor Murray Cairns, Professor Hubert Hondermarck, Professor Xu Dong Zhang, Associate Professor Estelle Sontag, Doctor Chen Chen Jiang, Associate Professor Liz Milward, Doctor Jean-Marie Sontag, Associate Professor Paul Tooney, Doctor Severine Roselli, Doctor Matt Dun, Doctor Chris Dayas, Doctor Lin Kooi Ong, Professor Dirk Van Helden, Mr Ben Copeland, Doctor Gabrielle Briggs, Emeritus Professor Leonie Ashman, Emeritus Professor John Rostas
SchemeRole
Equipment GrantInvestigator
Total AmountFunding StartFunding Finish
$24,59620132013
GNo:G1201189

Proteomics of Cancer$6,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Matt Dun, Doctor Nikki Verrills, Dr Anoop Enjeti
SchemeRole
Project GrantInvestigator
Total AmountFunding StartFunding Finish
$6,00020132013
GNo:G1300054

2012 (8 grants)

The Hunter Cancer Biobank (HCB): Maximising community value through validation, annotation and distribution throughout NSW$292,300
Funding Body: Cancer Institute NSW

Project Team
Professor John Forbes, Conjoint Professor Stephen Ackland, Professor Rodney Scott, Conjoint Associate Professor Barbara Young, Professor Hubert Hondermarck, Emeritus Professor Leonie Ashman, Professor Xu Dong Zhang, Doctor Kelly Kiejda, Doctor Nikki Verrills, Doctor Jennette Sakoff, Ms Janine Lombard, Doctor Jude Weidenhofer, Doctor Pradeep Tanwar
SchemeRole
Infrastructure GrantsInvestigator
Total AmountFunding StartFunding Finish
$292,30020122014
GNo:G1200798

Activating a tumour suppressor for leukaemia therapy$260,000
Funding Body: Cancer Council NSW

Project Team
Doctor Nikki Verrills, Dr Anthony Don, Dr Anoop Enjeti, Associate Professor Jonathan Morris
SchemeRole
Research GrantChief Investigator
Total AmountFunding StartFunding Finish
$260,00020122014
GNo:G1100512

Activating a tumour suppressor for leukaemia therapy they receive$100,000
Funding Body: Cure Cancer Australia Foundation

Project Team
Doctor Nikki Verrills, Dr Anthony Don, Dr Anoop Enjeti, Associate Professor Jonathan Morris
SchemeRole
Research GrantChief Investigator
Total AmountFunding StartFunding Finish
$100,00020122012
GNo:G1200007

Microscopic illumination system for advanced fluorescent protein technology$34,000
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Doctor Rick Thorne, Professor Xu Dong Zhang, Conjoint Associate Professor Murray Cairns, Doctor Nikki Verrills, Doctor Charles De Bock, Doctor Jude Weidenhofer, Doctor Severine Roselli, Doctor Kathryn Skelding, Emeritus Professor Leonie Ashman, Professor Hubert Hondermarck
SchemeRole
Equipment GrantInvestigator
Total AmountFunding StartFunding Finish
$34,00020122012
GNo:G1100983

Activating a tumour suppressor for leukaemia therapy$20,000
Funding Body: University of Newcastle

Project Team
Doctor Nikki Verrills
SchemeRole
Near Miss GrantChief Investigator
Total AmountFunding StartFunding Finish
$20,00020122012
GNo:G1200678

Regulation of the cell cycle by phosphorylation dependent targeting of CaMKII$20,000
Funding Body: University of Newcastle

Project Team
Doctor Nikki Verrills, Doctor Kathryn Skelding, Emeritus Professor John Rostas, Associate Professor Phillip Dickson, Conjoint Professor Keith Jones
SchemeRole
Near Miss GrantChief Investigator
Total AmountFunding StartFunding Finish
$20,00020122012
GNo:G1200679

Role of CaMKII targeting in neuronal susceptibility to excitotoxic cell death$20,000
Funding Body: University of Newcastle

Project Team
Emeritus Professor John Rostas, Doctor Neil Spratt, Associate Professor Phillip Dickson, Doctor Nikki Verrills
SchemeRole
Near Miss GrantInvestigator
Total AmountFunding StartFunding Finish
$20,00020122012
GNo:G1200673

FASEB Protein Phosphatases, Snowmass, Colorado USA, 15 - 20 July 2012$1,500
Funding Body: University of Newcastle - Faculty of Health and Medicine

Project Team
Doctor Nikki Verrills
SchemeRole
Travel GrantChief Investigator
Total AmountFunding StartFunding Finish
$1,50020122012
GNo:G1200803

2011 (7 grants)

Molecular characterisation of TRAIL-regulated signal transduction pathways and their role in the development, persistence, and exacerbation of allergic airways disease$615,048
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Professor Joerg Mattes, Doctor Nikki Verrills
SchemeRole
Project GrantInvestigator
Total AmountFunding StartFunding Finish
$615,04820112013
GNo:G1000314

Targeting a tumour suppressor, PP2AS for new Leukaemia therapies$600,000
Funding Body: Cancer Institute NSW

Project Team
Doctor Nikki Verrills
SchemeRole
Early Career FellowshipChief Investigator
Total AmountFunding StartFunding Finish
$600,00020112016
GNo:G1000861

Chemical Biology$444,961
Funding Body: University of Newcastle

Preclinical testing of PP2A activating compounds for the treatment of childhood acute lymphoblastic leukaemia$40,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Nikki Verrills, Dr Anthony Don
SchemeRole
Paediatric Oncology Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$40,00020112011
GNo:G1001001

Regulation of Breast Cancer Growth by a Novel Phosphorylation-Dependent Targeting Mechanism$35,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Kathryn Skelding, Doctor Nikki Verrills, Emeritus Professor John Rostas
SchemeRole
Breast Cancer Project GrantInvestigator
Total AmountFunding StartFunding Finish
$35,00020112011
GNo:G1001005

Targeting PP2A as a Novel Therapeutic Strategy for mutant FLT3* Acute Myeloid Leukaemia$25,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Nikki Verrills, Doctor Kyu-Tae Kim, Dr Anoop Enjeti
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$25,00020112011
GNo:G1000990

IMPLEN NanoPhotometer pearl$10,000
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Conjoint Associate Professor Murray Cairns, Associate Professor Paul Tooney, Associate Professor Alan Brichta, Emeritus Professor John Rostas, Emeritus Professor Patricia Michie, Conjoint Professor Keith Jones, Professor Ulli Schall, Associate Professor Phillip Dickson, Doctor Frederick Walker, Doctor Rick Thorne, Doctor Chris Dayas, Doctor Nikki Verrills, Doctor Janet Holt, Doctor Severine Roselli, Doctor Kathryn Skelding, Doctor Jude Weidenhofer, Associate Professor Liz Milward, Doctor Charles De Bock, Doctor Julie Merriman-Jones, Doctor Jing Qin Wu, Doctor Bing Liu, Mr Dan Johnstone, Ms Belinda Goldie, Ms Natalie Beveridge
SchemeRole
Equipment GrantInvestigator
Total AmountFunding StartFunding Finish
$10,00020112011
GNo:G1100030

2010 (4 grants)

An Integrated LC-MS-NMR facility for Applications in Proteomics and Organic Chemistry$500,000
Funding Body: ARC (Australian Research Council)

Project Team
Professor Adam McCluskey, Laureate Professor John Aitken, Professor Paul Dastoor, Professor Phillip Robinson, Professor Eileen McLaughlin, Emeritus Professor Geoffrey Lawrance, Professor Marcel Maeder, Professor Hugh Dunstan, Doctor Shaun Roman, Associate Professor Rob Atkin, Doctor Clovia Holdsworth, Doctor Mark Baker, Doctor Nikki Verrills, Professor Gottfried Otting, Associate Professor Brett Nixon, Doctor Xiaojing Zhou, Ms Megan Chircop, Doctor Warwick Belcher
SchemeRole
Linkage Infrastructure Equipment & Facilities (LIEF)Investigator
Total AmountFunding StartFunding Finish
$500,00020102010
GNo:G0190402

An Integrated LC-MS-NMR facility for Applications in Proteomics and Organic Chemistry$280,000
Funding Body: University of Newcastle

ABI 7500 Real Time PCR System $34,000
Funding Body: NHMRC (National Health & Medical Research Council)

Epigenetic methylation of PP2A subunit promoters in breast cancer$25,000
Funding Body: Hunter Children`s Research Foundation

Project Team
Doctor Nikki Verrills, Doctor Martin Horan
SchemeRole
Research GrantChief Investigator
Total AmountFunding StartFunding Finish
$25,00020102010
GNo:G0900148

2009 (4 grants)

An Advanced Mass Spectrometry Facility for Applications in Proteomics and Organic Chemistry$495,000
Funding Body: ARC (Australian Research Council)

Tetraspanin proteins in prostate cancer progression and prognosis$341,000
Funding Body: Cancer Council NSW

Project Team
Emeritus Professor Leonie Ashman, Doctor Nikki Verrills, Conjoint Professor Jim Denham
SchemeRole
Research GrantInvestigator
Total AmountFunding StartFunding Finish
$341,00020092011
GNo:G0188877

Confocal Laser Scanning Microscopy for Live Cell Imaging$275,000
Funding Body: ARC (Australian Research Council)

An Advanced Mass Spectrometry Facility for Applications in Proteomics and Organic Chemistry$50,000
Funding Body: ARC (Australian Research Council)

2008 (5 grants)

HMRI Cancer Research Program - MRSP Infrastructure$1,031,290
Funding Body: Hunter Medical Research Institute

Project Team
Conjoint Professor Stephen Ackland, Emeritus Professor Leonie Ashman, Professor John Forbes, Conjoint Professor Jim Denham, Conjoint Professor Peter Hersey, Professor Gordon Burns, Professor Adam McCluskey, Doctor Nikki Verrills
SchemeRole
NSW MRSP Infrastructure GrantInvestigator
Total AmountFunding StartFunding Finish
$1,031,29020082009
GNo:G0188622

PP2A: a novel target for leukaemia therapy$300,000
Funding Body: Cancer Council NSW

Project Team
Doctor Nikki Verrills, Emeritus Professor Leonie Ashman, Professor Alistair Sim, Associate Professor Danilo Perrotti, Assoc. Prof Timothy Hughes, Dr David Thomas
SchemeRole
Research GrantChief Investigator
Total AmountFunding StartFunding Finish
$300,00020082010
GNo:G0187694

Functional investigations of novel SET splice isoforms in acute myeloid leukaemia and their potential as a therapeutic target.$270,000
Funding Body: Anthony Rothe Memorial Trust

Project Team
Doctor Nikki Verrills
SchemeRole
Research GrantChief Investigator
Total AmountFunding StartFunding Finish
$270,00020082010
GNo:G0188185

Novel Alternative Splice Isoforms of the SET Oncogene in Acute Myeloid Leukaemia $25,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Nikki Verrills
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$25,00020082008
GNo:G0188462

PP2A: A new target for asthma therapy$20,000
Funding Body: University of Newcastle

Project Team
Professor Alistair Sim, Doctor Nikki Verrills, Professor John Scott, Conjoint Professor Peter Wark
SchemeRole
Near Miss GrantInvestigator
Total AmountFunding StartFunding Finish
$20,00020082008
GNo:G0188395

2007 (7 grants)

FACSAria - Fluorescence activated cell sorter$300,000
Funding Body: Cancer Institute NSW

Project Team
Doctor Nikki Verrills, Emeritus Professor Leonie Ashman, Laureate Professor John Aitken, Professor Eileen McLaughlin, Professor Alistair Sim, Doctor Rick Thorne, Doctor Jennette Sakoff
SchemeRole
Infrastructure GrantsChief Investigator
Total AmountFunding StartFunding Finish
$300,00020072007
GNo:G0187666

The role of protein phosphatase 2A in breast cancer$75,000
Funding Body: Cure Cancer Australia Foundation

Project Team
Doctor Nikki Verrills
SchemeRole
Research GrantChief Investigator
Total AmountFunding StartFunding Finish
$75,00020072007
GNo:G0186797

HMRI Contribution toward FACSAria - Fluorescence activated cell sorter$52,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Nikki Verrills, Emeritus Professor Leonie Ashman, Laureate Professor John Aitken, Professor Eileen McLaughlin, Professor Alistair Sim, Doctor Rick Thorne, Doctor Jennette Sakoff
SchemeRole
Equipment GrantChief Investigator
Total AmountFunding StartFunding Finish
$52,00020072007
GNo:G0188207

Differential regulation of human mast cell degranulation by discrete forms of protein phosphatase 2A$50,000
Funding Body: Asthma Foundation of New South Wales

Project Team
Professor Alistair Sim, Doctor Nikki Verrills, Professor Paul Foster, Conjoint Professor Peter Wark, Conjoint Professor Peter Gibson, Dr Gregory Kranias
SchemeRole
Research GrantInvestigator
Total AmountFunding StartFunding Finish
$50,00020072007
GNo:G0187247

The tumour suppressor gene, PP2A, in breast cancer and its potential as a new target for therapy$29,930
Funding Body: Ramaciotti Foundations

Project Team
Doctor Nikki Verrills
SchemeRole
Research GrantChief Investigator
Total AmountFunding StartFunding Finish
$29,93020072007
GNo:G0188055

Polymerase Chain Reaction (PCR) machine and Spectrophotometer$20,000
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Emeritus Professor Leonie Ashman, Professor Alistair Sim, Doctor Nikki Verrills
SchemeRole
Equipment GrantInvestigator
Total AmountFunding StartFunding Finish
$20,00020072007
GNo:G0188195

American Association of Cancer Research, LA Convention Centre, Los Angeles, USA, 14/4/2007 - 18/4/2007$1,700
Funding Body: University of Newcastle

Project Team
Doctor Nikki Verrills
SchemeRole
Travel GrantChief Investigator
Total AmountFunding StartFunding Finish
$1,70020072007
GNo:G0187550

2006 (6 grants)

The role of protein phosphates in regulating the cytoskeletal dynamics of cancer cells$292,062
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Doctor Nikki Verrills
SchemeRole
Training (Postdoctoral) Fellowships - Peter Doherty Biomedical Fellowship (Australia)Chief Investigator
Total AmountFunding StartFunding Finish
$292,06220062010
GNo:G0185634

Live cell imaging facility$149,100
Funding Body: Cancer Institute NSW

Project Team
Doctor Rick Thorne, Doctor Nikki Verrills, Professor Alistair Sim, Professor Gordon Burns
SchemeRole
Infrastructure GrantsInvestigator
Total AmountFunding StartFunding Finish
$149,10020062006
GNo:G0186146

Investigating the functional role of altered expression and point mutations in the tumour suppressor gene PP2A$50,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Nikki Verrills
SchemeRole
Special Competitive Research Fund for Early Career Researchers in CancerChief Investigator
Total AmountFunding StartFunding Finish
$50,00020062007
GNo:G0186082

Novel protein phosphatase interactions in cancer$10,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Nikki Verrills, Professor Alistair Sim
SchemeRole
Project GrantChief Investigator
Total AmountFunding StartFunding Finish
$10,00020062006
GNo:G0186480

High speed computer for a live cell imaging system$3,000
Funding Body: Hunter Medical Research Institute

Project Team
Doctor Rick Thorne, Professor Gordon Burns, Doctor Nikki Verrills, Professor Alistair Sim
SchemeRole
Equipment GrantInvestigator
Total AmountFunding StartFunding Finish
$3,00020062006
GNo:G0187279

BioRad Mini-PROTEAN3 Electrophoresis system$995
Funding Body: Hunter Medical Research Institute

Project Team
Emeritus Professor Leonie Ashman, Associate Professor Phillip Dickson, Emeritus Professor Peter Dunkley, Emeritus Professor John Rostas, Professor Judith Scott, Professor Alistair Sim, Doctor Nikki Verrills
SchemeRole
Equipment GrantInvestigator
Total AmountFunding StartFunding Finish
$99520062006
GNo:G0187280

2005 (1 grants)

Europhosphatases Conference 2005, 10-14 July 2005$2,430
Funding Body: University of Newcastle

Project Team
Doctor Nikki Verrills
SchemeRole
Travel GrantChief Investigator
Total AmountFunding StartFunding Finish
$2,43020052005
GNo:G0185546

2004 (1 grants)

12th International Conference on Second Messenger and Phosphoproteins, 3-7 August 2004$2,400
Funding Body: University of Newcastle

Project Team
Doctor Nikki Verrills
SchemeRole
Travel GrantChief Investigator
Total AmountFunding StartFunding Finish
$2,40020042004
GNo:G0184543
Edit

Research Supervision

Number of current supervisions4
Total current UoN PhD EFTSL0.6

For supervisions undertaken at an institution other that the University of Newcastle, the institution name is listed below the program name.

Current Supervision

CommencedProposed
Completion
ProgramSupervisor TypeResearch Title
20142018PhD (Medical Biochemistry)Principal SupervisorIdentification of the Mechanism of Action of Anti-cancer Drugs Targeting Activation of the Tumour Suppressor, PP2A
20072010PHD Biochemistry & Cell Biology
University of Newcastle
Co-SupervisorThe role of protein phosphatases in breast cancer
20062009PHD Biochemistry & Cell Biology
University of Newcastle
Co-SupervisorRole of PP2A in cancer
20062009PHD Biochemistry & Cell Biology
University of Newcastle
Co-SupervisorPP2A in mast cell function

Past Supervision

YearProgramSupervisor TypeResearch Title
2014PhD (Medical Biochemistry)Principal SupervisorTargeting PP2A Activation as a Novel Therapeutic Strategy for Receptor Tyrosine Kinase Driven Leukemia
2012PhD (Medical Biochemistry)Principal SupervisorThe Role of Protein Phosphatase 2A as a Tumour Suppressor in Breast Cancer
2011PhD (Medical Biochemistry)Principal SupervisorRegulation of Mast Cell Degranulation by Protein Phosphatase 2A
2010PhD (Medical Biochemistry)Principal SupervisorRegulation of the Tumour Suppressor PP2A by Oncogenic Tyrosine Kinases
Edit

Dr Nicole (Nikki) Verrills

Work Phone(02) 4921 5619
Fax(02) 4921 6903
Email
PositionResearch Fellow
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine
The University of Newcastle, Australia
Focus AreaMedical Biochemistry
Office
LS3-46,
Life Sciences,
Callaghan
University Drive
Callaghan NSW 2308
Australia
URL:www.newcastle.edu.au/profile/nikki-verrills